149 related articles for article (PubMed ID: 20470747)
21. Apolipoprotein A-I peptide models as probes to formulate potential inhibitors of the low-density lipoprotein oxidation.
Darvari MI; Petraki MP; Tellis C; Harilogis K; Tselepis AD; Sakarellos-Daitsiotis M
J Pept Sci; 2011 Nov; 17(11):720-5. PubMed ID: 21948303
[TBL] [Abstract][Full Text] [Related]
22. Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation.
Stewart CR; Wilson LM; Zhang Q; Pham CL; Waddington LJ; Staples MK; Stapleton D; Kelly JW; Howlett GJ
Biochemistry; 2007 May; 46(18):5552-61. PubMed ID: 17429947
[TBL] [Abstract][Full Text] [Related]
23. Iron-catalyzed oxidation of Trp residues in low-density lipoprotein.
Chen HH; Chen CY; Chow LP; Chen CH; Lee YT; Smith CV; Yang CY
Biol Chem; 2011 Oct; 392(10):859-67. PubMed ID: 21848505
[TBL] [Abstract][Full Text] [Related]
24. Method to site-specifically identify and quantitate carbonyl end products of protein oxidation using oxidation-dependent element coded affinity tags (O-ECAT) and nanoliquid chromatography Fourier transform mass spectrometry.
Lee S; Young NL; Whetstone PA; Cheal SM; Benner WH; Lebrilla CB; Meares CF
J Proteome Res; 2006 Mar; 5(3):539-47. PubMed ID: 16512668
[TBL] [Abstract][Full Text] [Related]
25. The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.
Staprans I; Pan XM; Rapp JH; Feingold KR
Mol Nutr Food Res; 2005 Nov; 49(11):1075-82. PubMed ID: 16270280
[TBL] [Abstract][Full Text] [Related]
26. Secondary radicals derived from chloramines of apolipoprotein B-100 contribute to HOCl-induced lipid peroxidation of low-density lipoproteins.
Hazell LJ; Davies MJ; Stocker R
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):489-95. PubMed ID: 10215584
[TBL] [Abstract][Full Text] [Related]
27. Rapid identification of comigrating gel-isolated proteins by ion trap-mass spectrometry.
Arnott D; Henzel WJ; Stults JT
Electrophoresis; 1998 May; 19(6):968-80. PubMed ID: 9638943
[TBL] [Abstract][Full Text] [Related]
28. Direct evidence for apo B-100-mediated copper reduction: studies with purified apo B-100 and detection of tryptophanyl radicals.
Batthyány C; Santos CX; Botti H; Cerveñansky C; Radi R; Augusto O; Rubbo H
Arch Biochem Biophys; 2000 Dec; 384(2):335-40. PubMed ID: 11368321
[TBL] [Abstract][Full Text] [Related]
29. Comparative time-courses of copper-ion-mediated protein and lipid oxidation in low-density lipoprotein.
Knott HM; Baoutina A; Davies MJ; Dean RT
Arch Biochem Biophys; 2002 Apr; 400(2):223-32. PubMed ID: 12054433
[TBL] [Abstract][Full Text] [Related]
30. Low-density lipoprotein oxidation.
Iuliano L; Micheletta F; Violi F
Ital Heart J; 2001 Dec; 2(12):867-72. PubMed ID: 11838329
[TBL] [Abstract][Full Text] [Related]
31. Site-specific glycosylation analysis of human apolipoprotein B100 using LC/ESI MS/MS.
Harazono A; Kawasaki N; Kawanishi T; Hayakawa T
Glycobiology; 2005 May; 15(5):447-62. PubMed ID: 15616123
[TBL] [Abstract][Full Text] [Related]
32. Characterization of oxidized phospholipids in oxidatively modified low density lipoproteins by nanoflow liquid chromatography-tandem mass spectrometry.
Lee JY; Lim S; Park S; Moon MH
J Chromatogr A; 2013 May; 1288():54-62. PubMed ID: 23523068
[TBL] [Abstract][Full Text] [Related]
33. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
[TBL] [Abstract][Full Text] [Related]
34. Use of an integrated MS--multiplexed MS/MS data acquisition strategy for high-coverage peptide mapping studies.
Chakraborty AB; Berger SJ; Gebler JC
Rapid Commun Mass Spectrom; 2007; 21(5):730-44. PubMed ID: 17279597
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune responses against the apo B-100 LDL receptor-binding site protect against arterial accumulation of lipids in LDL receptor deficient mice.
Fredrikson GN; Lindholm MW; Ljungcrantz I; Söderberg I; Shah PK; Nilsson J
Autoimmunity; 2007 Mar; 40(2):122-30. PubMed ID: 17453711
[TBL] [Abstract][Full Text] [Related]
36. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation.
Miller YI; Felikman Y; Shaklai N
Arch Biochem Biophys; 1996 Feb; 326(2):252-60. PubMed ID: 8611031
[TBL] [Abstract][Full Text] [Related]
37. Complete protein sequence and identification of structural domains of human apolipoprotein B.
Knott TJ; Pease RJ; Powell LM; Wallis SC; Rall SC; Innerarity TL; Blackhart B; Taylor WH; Marcel Y; Milne R
Nature; 1986 Oct 23-29; 323(6090):734-8. PubMed ID: 3773997
[TBL] [Abstract][Full Text] [Related]
38. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100.
Yang CY; Chen SH; Gianturco SH; Bradley WA; Sparrow JT; Tanimura M; Li WH; Sparrow DA; DeLoof H; Rosseneu M
Nature; 1986 Oct 23-29; 323(6090):738-42. PubMed ID: 3095664
[TBL] [Abstract][Full Text] [Related]
39. Identification of racemization sites using deuterium labeling and tandem mass spectrometry.
Huang L; Lu X; Gough PC; De Felippis MR
Anal Chem; 2010 Aug; 82(15):6363-9. PubMed ID: 20669991
[TBL] [Abstract][Full Text] [Related]
40. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques.
Leeuwenburgh C; Rasmussen JE; Hsu FF; Mueller DM; Pennathur S; Heinecke JW
J Biol Chem; 1997 Feb; 272(6):3520-6. PubMed ID: 9013599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
